Idiopathic Pulmonary Fibrosis (IPF) is a condition where the lungs become progressively scarred. Many clinical and radiological syndromes are described on the basis of the pattern of involvement of the lungs. It is rare before the age of 50; usually the disease starts after age 60 and is most prevalent in the age group after 70 – 75 years. It is hitherto unknown what causes the disease but several hypotheses including immune mechanism to lungs and environmental toxins have been postulated.
In IPF the tiniest air sac of the lungs called alveoli get progressively damaged and eventually get scarred. The lung therefore gets progressively stiff. It becomes difficult for Oxygen to pass from the lungs to the blood stream through the damaged alveoli. It also becomes more and more difficult for the lungs to expand during breathing as it becomes scarred and stiff. As a result patients start to get breathless on exertion.
The cause of IPF, i.e. what causes the process of damage in the alveoli is as yet unknown. Several mechanisms are postulated and are believed to be associated with the disease. However a direct causal relationship has not been established.
Postulated mechanisms are:
As detailed above the reason as to why the process of damage begins, why it happens after a certain age and whether one of the factors above directly causes IPF is not known.
Diagnosis of IPF is based on a combination of clinical history & examination, laboratory tests, tests of lungs and its functions and radiological investigations.
Currently there is no treatment to cure IPF. The treatments available aim to reduce the progression of the disease or relieve symptoms.
• Medicine: There are 2 medicines currently available which has been shown to be of some value in IPF and is able to slow down the progression of the disease. They are useful once the function of the lungs have gone down to 50 -80% of normal. The medicines are called Pirfenidone and Nintedanib. In addition N-Acetylcysteine, a medicinal product with antioxidant properties have shown some evidence to be effective in IPF, although this is controversial.
• Pulmonary Rehabilitation: Several programs with breathing exercises and physical activity can increase the capacity of the lungs and improve symptoms of breathlessness.
• Oxygen Therapy: IPF causes the levels of Oxygen in the blood stream to fall resulting in breathlessness. In advanced stages of disease therapy with oxygen can improve oxygen levels in the blood and improve symptoms.
• Self Care: There are several things the patients can do to improve their symptoms. These include
2. Stopping smoking
3. Eating a healthy diet
4. Taking yearly influenza vaccinations
5. Taking precaution to stay away from people with chest infections.
• Lung Transplant: Lung transplant can significantly improve life expectancy in patients with IPF. However it’s major operation of significant undertaking. The success of the procedure depends on the patient’s general health and condition of the lungs. Donor lungs compatible to the patient’s body have always been scarce to find.
• Palliative care: IPF can sometimes be very aggressive and not respond to any forms of treatment. Sometimes there is nothing more for doctors to do other than offer symptom control through palliative care.
Choose between Online Or Video As Your Preferred Mode Of Consultation With The Consultant
In this section upload patient details, medical history, current medications taken and the necessary report to discuss the case with the consultant
In this section you pay and book for your consultation
With Online Query Consultation, the consultant replies to your queries within 24-48 hours from the time the consultation is booked.
With Video Consultation, the consultant reviews your case and consults with you on the day the consultation is booked